3rd Quarter - Report

CARIS LIFE SCIENCES, INC. for CARIS LIFE SCIENCES, INC.

Firm
Client
Income
—
Expenses
$56,867
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organization, Sustainable Growth Rate reform, pathology reimbursement issues.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to Speaker of the House for Policy

Contacted: Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Medicare/Medicaid MMM

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA)

Insurance INS

Reimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reform, preventing co-payments for lab services, and accountable care organizations, Sustainable Growth Rate reform, pathology reimbursement.

LobbyistCovered position, as disclosed
AMY JENSEN CUNNIFFE Asst. to the Speaker of the House for Policy

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.